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A B S T R A C T
The communication of laboratory results to physicians and the quality of reports represent fundamental re-
quirements of the post-analytical phase in order to assure the right interpretation and utilization of laboratory
information. Accordingly, the International Standard for clinical laboratories accreditation (ISO 15189) requires
that “laboratory reports shall include the information necessary for the interpretation of the examination re-
sults”. Measurement uncertainty (MU) is an inherent property of any quantitative measurement result which
express the lack of knowledge of the true value and quantify the uncertainty of a result, incorporating the factors
known to inﬂuence it. Even if the MU is not included in the report attributes of ISO 15189 and cannot be
considered a post-analytical requirement, it is suggested as an information which should facilitate an appropriate
interpretation of quantitative results (quantity values). Therefore, MU has two intended uses: for laboratory
professionals, it gives information about the quality of measurements, providing evidence of the compliance
with analytical performance characteristics; for physicians (and patients) it may help in interpretation of
measurement results, especially when values are compared with reference intervals or clinical decision limits,
providing objective information. Here we describe the way that MU should be added to laboratory reports in
order to facilitate the interpretation of laboratory results and connecting eﬀorts performed within laboratory to
provide more accurate and reliable results with a more objective tool for their interpretation by physicians.
1. Introduction
Uncertainty is ubiquitous in medicine, as well emphasized by the
Osler's maxim “medicine is a science of uncertainty and an art of
probability” [1]. However, uncertainty is often ignored as a subject in
medicine, its importance underappreciated and its consequences sup-
pressed [2]. In particular, despite signiﬁcant advances in diagnostic
testing, physicians still face uncertainty in interpretation, particularly
in laboratory testing, and an evidence collected in the last few decades
clearly demonstrates the high rates of errors in interpreting laboratory
results [3]. As highlighted more than 40 years ago, the “brain-to-brain
loop” in laboratory testing was conceptualized as a continuum from
several steps until a right interpretation and utilization of the labora-
tory information is achieved to provide improved clinical and eco-
nomical outcomes [4]. However, the need for systematic feedback to
improve the value of laboratory services has been poorly understood
and, even more risky, poorly applied in daily laboratory practice,
mainly due to the focus on analytical quality while overlooking the
importance of extra-analytical phases [5]. This in turn, lead to view the
“brain-to-brain loop” as an open-loop system, sometimes called a “non-
feedback controlled system”, and more recently, it was emphasized the
need to close the loop by evaluating the appropriateness of all steps of
the total testing process, including clinical and economical outcomes
[6].
2. Laboratory reports
The notiﬁcation of laboratory results to physicians and the quality
of reports represent fundamental requirements of the post-analytical
phase in order to assure the right interpretation and utilization of la-
boratory information. Diagnostic uncertainty may derive from in-
complete information in laboratory reports, leading to an increased risk
of inappropriate interpretation of laboratory data. According to the ISO
15189 (subclause 5.8.1), laboratory “reports shall include the in-
formation necessary for the interpretation of the examination results”
[7]. This in turn, means that, at least, in addition to “examination re-
sults reported in SI units, units traceable to SI units, or other applicable
units, biological reference intervals, clinical decision values, or dia-
grams/nomograms supporting clinical decision values, where applic-
able”, the following report attributes are needed “to eﬀectively
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communicate laboratory results and meet the users' needs”:
a) comments on sample quality that might compromise examination
results;
b) comments regarding sample suitability with respect to acceptance/
rejection criteria;
c) critical results, where applicable;
d) interpretive comments on results, where applicable, which may in-
clude the veriﬁcation of the interpretation of automatically selected
and reported results (see 5.8.2) in the ﬁnal report. [7]
Regarding the measurement uncertainty (MU), in the clause 5.5
“Examination processes”, it is included the subclause 5.5.1.4
“Measurement uncertainty of measured quantity values” that cites:
“The laboratory shall consider measurement uncertainty when inter-
preting measured quantity values. Upon request, the laboratory shall
make its estimates of measurement uncertainty available to laboratory
users” [7]. Therefore, even if the MU is not included in the report at-
tributes and cannot be considered a post-analytical requirement, it is
suggested as an information which should facilitate an appropriate in-
terpretation of quantitative results (quantity values). In fact, for many
laboratory tests, particularly those with a strong impact in the clinical
decision-making, the presence in the report of the simple numerical
value does not immediately provide clinicians with an interpretation.
For many laboratory tests, the analytical quality (based on established
performance speciﬁcations) and the biological content are strictly re-
lated and interconnected. Therefore, a correct interpretation is possible
only knowing the uncertainty of laboratory results, which derives from
both analytical (e.g. bias and imprecision) and biological variability, as
well as from other possible sources [8]. The knowledge of biological
variation, namely the within-subject biological variation (CVI) of re-
quested measurands, represents a fundamental issue for a correct in-
terpretation of laboratory results, particularly when serial measure-
ments are requested for disease/therapy monitoring. In these situations,
the use of the reference change value (RCV) has been advocated as a
most appropriate tool for monitoring individuals [9]. When the result is
compared with a reference interval (RI) or a decision limit, the need
that clinicians should take into account the biological variation is
clearly acknowledged in some clinical guidelines, such as for medical
care in diabetes [10], and in providing evidence-base recommendations
on retesting times [11]. However, the combination of the biological
variation with MU in a laboratory report when data are compared to the
reference interval (RI) or a decision limit seems a more complex matter.
3. Measurement uncertainty
MU is a inherent property of any quantitative measurement result
which expresses the lack of knowledge of the true value of the result
and incorporate the factors known to inﬂuence it. As variability of la-
boratory results is unavoidable, “the result of any measurement re-
presents an approximation or estimate of the value of a measurand and
thus is complete only when accompanied by a statement of the un-
certainty of that estimate” [12]. MU is not only a quantiﬁcation of the
doubt about the measurement result and an essential indicator of the
result quality, but essential information without which measurement
results should not be meaningfully interpreted. Fig. 1 shows the main
goals of MU.
For laboratory professionals, it gives information about the quality
of measurements, providing evidence of the compliance with analytical
performance characteristics (as expression of imprecision and bias of
the analytical system) and monitoring these performances over time.
Moreover, it should be used for comparing the metrological quality
either of diﬀerent clinical laboratories or of diﬀerent analytical
methods as well as diﬀerent platforms/systems.
For physicians (and patients) it helps in interpretation of measure-
ment results, providing objective information.
For the purpose of quality assurance, in fact, the standard un-
certainty and bias should be obligatory and regularly assessed [13] and
compared with other from other clinical laboratories as a benchmark
and for continuous improvement programs.
For the purpose of allowing a better interpretation of laboratory
data, it should be emphasized that a laboratory result per se has no
informative value as it has always to be interpreted by comparison. The
comparator should be the reference interval (RI), a decision limit and/
or a previously obtained result on the same measurand, depending on
the ﬁt-for-purpose of test results. RIs are typically statistical conﬁdence
limits for the typical spread of results to be found in a healthy reference
population. There are some special forms of reference limits for sub-
stances not normally found in healthy people such as therapeutic ranges
for drug levels, detection limits for toxins (or drugs of abuse), legal
limits such as for alcohol. In contrast to reference intervals, which are
designed to conﬁrm health (absence of any disease) with high speciﬁcity
(typically 95%), clinical decision limits are more clinically focused and
generally aim to conﬁrm the presence of a particular disease or clinical
risk with appropriately high sensitivity [14]. Particularly when a result
falls close to the upper or lower limits of the RI, or near to the clinical
decision limit, MU can give a clear information and avoid any mis-
classiﬁcation that should change the diagnosis and treatment of the
patient. When laboratory tests are prevalently used for monitoring a
disease (e.g. disease progression and recurrence) or when the in-
dividuality index (II) of a measurand is below 0.6 because patients vary
much more from one to another than they do individually from day to
day (CVI < < CVG), the comparison of a result with the RI is of scarce
usefulness. In these situations, the comparison of the result of the
measurand with a previously obtained one, and the reference change
value (RCV) represent valuable information. The RCV basically evalu-
ates whether the diﬀerence in numerical results is greater than the
combined variation (analytical and biological) inherent in the two re-
sults. However, recently some important considerations have developed
regarding the adoption of RCV then more than two serial results are
considered in the calculation [15].
4. Communication of measurement uncertainty to clinician: the
past
In 2004, we have formulated a proposal on the communication of
MU to clinicians, which should be summarized as follows [16]:
1) “For tests with a uni-modal distribution, the adoption of a decision
limit should replace the report the traditional reference value that,
Fig. 1. Summary of the main goals of measurement uncertainty.
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in this particular context, can only create confusion. No information
on laboratory uncertainty should be added to the report, but the
laboratory is responsible for reducing as far as possible imprecision
and bias at the decision level. This can be done by creating analy-
tical quality, by selecting methods and diagnostic systems that allow
the containment of analytical bias and imprecision, by introducing
an internal quality control process speciﬁcally designed for mon-
itoring the compliance to quality speciﬁcations, and by attending a
valuable external quality scheme. Finally, a careful control of pre-
analytical variables is mandatory, mainly for analytes such as glu-
cose [16].
2) For tests with bi-modal distributions, in addition to traditional re-
ference values, some ﬂags can be added to help clinicians interpret
laboratory data. In particular, some ﬂags can indicate data higher or
lower than the upper and the lower reference limits, respectively,
and likely to be of clinical importance on the basis of analytical and
biological variation. Other ﬂags can indicate highly signiﬁcant
changes in serial results, in particular in comparing the present
ﬁnding with the previous one on the basis of the reference change
value [17].
3) For tests used in patients monitoring and in evaluating the response
to therapy (serial measurements), the reference change value or the
most eﬀective threshold of the diﬀerence between two consecutive
results should be indicated, as recently described for biochemical
markers of bone turnover [18–19].
4) For tests/test batteries that require interpretive comments, these
should be added to the report as well as discussed in multi-
disciplinary meetings and interpretive rounds to spread the knowl-
edge on a more objective evaluation of laboratory data”.
Thereafter, we translated the proposal into clinical practice by
adding to laboratory reports:
a) the TE obtained in our laboratory according to the imprecision (data
from the internal quality control (IQC) at a concentration near to the
decision level) and bias (data from the external quality assurance
schemes), as shown in Fig. 2;
b) the RCV for measurands primarily used in patient monitoring (e.g.
tumor and bone markers), based on the imprecision and the biolo-
gical variation (data from the Westgard database), as shown in
Fig. 3.
After an initial concern by some physicians, particularly related to
the term “total error” which was interpreted in a negative sense, most
users expressed satisfaction for this additional information, particularly
regarding the RCV. A huge interest was expressed by students attending
the medical degree and post-graduated courses, namely after a series of
teaching and educational initiatives on the concept of biological var-
iation, quality speciﬁcations and related performance characteristics.
5. Communication of measurement uncertainty to clinician: a new
proposal
The debate on the methods for quantifying the quality of laboratory
performances, and in particular advantages and disadvantages of the TE
theory and the related calculation of allowable TE (ATE), in comparison
to the MU is still open with many papers already published [20] and we
do not like to further discuss this point. However, answering to the
question “when and how” should we have to communicate MU to
physicians, we have recently described three diﬀerent scenarios to add
MU in laboratory reports. The diﬀerent scenarios apply to the type of
information usually included in laboratory reports in order to facilitate
the interpretation of results, that are: a) the measurand RI, b) diagnostic
cut-oﬀs and decision limits, and, ﬁnally, c) the RCV [21].
a) When the test result is compared with the RI, there are three options
to include MU in the report, as shown in Fig. 4 MU should be added
to the analytical result as a number, as a percentage (%), or as the
“conﬁdence interval” with a deﬁned conﬁdence level (e.g. 95%)
calculated for the measured value on the basis of the laboratory-
speciﬁc imprecision; this means that a given result has a probability
of 95% of being included in that interval. The most appropriate
option seems to be the last one, as the physician has not to calculate
the “conﬁdence interval” which is directly provided in the report.
This in turn requires a sophisticated Laboratory Information System
(LIS) able to calculate for the single measurand the interval of
conﬁdence based on the analytical imprecision at the speciﬁc con-
centration level of the measurand, when appropriated [22].
b) Where a test result is compared with a clinical decision point (e.g.
cut-oﬀ, decision limit and/or critical value), the MU calculation
should include not only the imprecision but also the bias and the
uncertainty bias. For example, this should be applied to some
measurands such as glucose, HbA1c and cardiac troponin [21].
c) Finally, when test results are primarily used for monitoring disease
and/or therapy, the MU estimation seems of poor clinical value,
being the RCV the most appropriate information.
Notably, in all previously reported scenarios, laboratory reports
should include the information regarding the conﬁdence levels used to
calculate expanded MU (e.g. 95% conﬁdence in case of using a coverage
factor k = 2).
6. Analytical and total quality
While the quality of analysis is undoubtedly important, so too is the
quality of the ﬁnal report including its RIs, clinical interpretations and
notiﬁcations. These contain the information and knowledge from la-
boratory specialists that should support clinical decision-making.
Quality in laboratory medicine has been deﬁned “an unﬁnished
journey” as further eﬀorts should be done for better establishing and
Fig. 2. Example of reporting of Total Error (TE) in medical report.
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monitoring analytical characteristics based on the hierarchy of perfor-
mance speciﬁcations [23] and to perform valuable quality control and
quality assurance procedures. In addition to a reliable analytical result,
however, the evidence collected in the last few years highlights the
need for valuable extra-analytical phases, major areas of concerns being
inappropriate request of laboratory tests and inappropriate interpreta-
tion of laboratory results [24]. Currently, most clinical laboratories
oﬀer a repertoire of well over hundreds of tests: some of these are fa-
miliar to all physicians, but others are less so. In addition, the im-
provement in diagnostic systems, and the adoption of more objective
quality speciﬁcations and more eﬀective quality control rules have al-
lowed clinical laboratories to provide results with a lower degree of
analytical uncertainty, consequent to reduced imprecision and bias. The
MU in many laboratory tests has been signiﬁcantly reduced over time,
but many clinicians are unaware of these improvements, and this can
cause them to under-utilize laboratory information both in diagnosis
and in patients management. In addition to the right measurement
units, right RIs and/or decision limits, the addition of MU in laboratory
reports may allow a more objective interpretation of laboratory data,
particularly for quantitative results. However, both for quantitative and
qualitative results, the interpretation of laboratory information should
always take into consideration the clinical context as well as a wide
consensus has been achieved on the evidence that interpretative com-
ments play a fundamental role in improving the interpretation of la-
boratory data, particularly in some complex diagnostic areas [25]. In
addition, the inclusion of the RCV in data used for patient/therapy
monitoring is the paradigm of a “personalized” approach to the inter-
pretation of laboratory results, based on the recognition of the im-
portance of the biological variation. The biological variation should be
taken into consideration by clinicians even when laboratory results are
compared to RIs or decision limits, particularly when the result is near
to the upper/lower limit of the RI or to the decision limit, as suggested
in many clinical guidelines.
In conclusion, performance speciﬁcations have been deﬁned as “the
level of performance required to facilitate clinical decision-making”
[17] as they set limits for a test to establish whether it is acceptable for
routine use [20]. However, it should be added to this deﬁnition, that
“they may allow a more objective interpretation of laboratory results”
thus connecting eﬀorts done within the laboratory with the due search
for total quality and patient safety in laboratory medicine.
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